Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation

Abstract

Methods for the treatment of CNS disorders using combinations of muscarinic activators and inhibitors, and medicaments comprising muscarinic activators and inhibitors.

We claim: 
     
         1 . A method of treating a central nervous system disorder comprising administering to a patient a muscarinic Activator with a muscarinic Inhibitor where the central nervous system disorder is selected from the following: schizophrenia, Disorders Related To Schizophrenia, Muscarinic Disorder, Movement Disorder, Mood Disorder, Cognitive Disorder, Attention Disorder, and Addictive Disorder. 
     
     
         2 . The method of  claim 1 , wherein the combination of the muscarinic Activator and the muscarinic Inhibitor has a theta score of greater than 230. 
     
     
         3 . The method of  claim 1 , wherein the muscarinic Inhibitor and the muscarinic Activator are administered simultaneously. 
     
     
         4 . The method of  claim 1 , wherein from 1 milligram to 1 gram of the muscarinic Activator is administered. 
     
     
         5 . The method of  claim 1 , wherein from 1 milligram to 1 gram of the muscarinic Inhibitor is administered. 
     
     
         6 . The method of  claim 1 , wherein the muscarinic Activator and the muscarinic Inhibitor are packaged in one dosage vehicle. 
     
     
         7 . The method of  claim 1 , wherein the muscarinic Activator and the muscarinic Inhibitor are formulated in an immediate release formulation. 
     
     
         8 . The method of  claim 1 , wherein the muscarinic Activator and the muscarinic Inhibitor are formulated in a controlled release formulation. 
     
     
         9 . The method of  claim 1 , wherein the muscarinic Activator and the muscarinic Inhibitor are administered in combination with a therapeutic agent. 
     
     
         10 . The method of  claim 9 , wherein the therapeutic agent is selected from an antipsychotic, an anxiolytic, an anti-depressant, a sedative, a tranquilizer, and combinations thereof. 
     
     
         11 . A medicament comprising a muscarinic Activator, a muscarinic Inhibitor, and a pharmaceutically acceptable carrier. 
     
     
         12 . The medicament of  claim 11 , wherein the combination of the muscarinic Activator and the muscarinic Inhibitor has a theta score of greater than 230. 
     
     
         13 . The medicament of  claim 11 , comprising from 1 milligram to 1 gram of the muscarinic Activator. 
     
     
         14 . The medicament of  claim 11 , comprising from 1 milligram to 1 gram of the muscarinic Inhibitor. 
     
     
         15 . The medicament of  claim 11 , which is in the form of a tablet, troche, liquid, emulsion, suspension, drops, capsule, gel cap, cream, gel, ointment, foam, cream, aerosol, suppository, enema, or vaginal ring. 
     
     
         16 . The medicament of  claim 11 , which is formulated as an immediate release formulation. 
     
     
         17 . The medicament of  claim 11 , which is formulated as a controlled release formulation.